ライフサイエンスコーパス: dentifrice

1 ice) and 2) placebo group (NSPT plus placebo dentifrice).

2 f from DH of a zinc-carbonate hydroxyapatite dentifrice.

3 FMUD and daily use of a triclosan/copolymer dentifrice.

4 s microbiologic counts compared with placebo dentifrice.

5 ce to a positive control triclosan/copolymer dentifrice.

6 the pyrophosphates to become soluble in the dentifrice.

7 may occur when pyrophosphates are added to a dentifrice.

8 iodontal parameters than NSPT plus a placebo dentifrice.

9 ) shown for those using the positive control dentifrice.

10 to a commercially available sodium fluoride dentifrice.

11 ther sodium and stannous fluoride containing dentifrices.

12 osphate (test) and sodium fluoride (control) dentifrices.

13 r commercially-available fluoride-containing dentifrices.

14 st a commercially available positive control dentifrice (0.30% triclosan/2.0% Gantrez copolymer).

15 Subjects using dentifrice 1 (D1) showed statistically significantly gre

16 sing a double-mask, randomized design, three dentifrices: 1) containing 8% arginine and 1,450 ppm sod

17 The participants used the dentifrices 2x/day for 8 weeks.

18 n group (NSPT plus medicated 2% atorvastatin dentifrice) and 2) placebo group (NSPT plus placebo dent

19 The triclosan-containing dentifrices are effective in controlling biofilm formati

20 ovements in tactile scores versus the KNO(3) dentifrice at Day 3 (p = 0.020).

21 had greater thermal improvements than KNO(3) dentifrice at Week 2 (p = 0.021) and in a random coeffic

22 etate-based dentifrice (group 2), and 29 the dentifrice based on zinc-carbonate hydroxyapatite (group

23 l soluble fluorides (TSF) in 5 child formula dentifrices (CFD) using Inter-method reliability (IMR) s

24 efore, was to determine efficacy of a SrAc2F dentifrice compared with KCl/MFP and a commercially avai

25 biologic effects of a commercially available dentifrice containing aloe vera on the reduction of plaq

26 f the study was to compare the efficacy of a dentifrice containing bioactive glass, 5% CSPS, and 8% a

27 Cl/MFP and a commercially available fluoride dentifrice containing sodium fluoride/sodium monofluorop

28 have demonstrated efficacy of desensitizing dentifrices containing strontium acetate/sodium fluoride

29 y were immediately applied with one of three dentifrices containing: 5% CSPS, 8% arginine, or control

30 efficacy between 1000- and 2500-ppm-fluoride dentifrices could be detected after 12 months.

31 dentifrice (n = 21) or triclosan-containing dentifrice ([CT] n = 18).

32 The CSPS and arginine dentifrices exhibited RS relief resulting from toothbrus

33 ice relative to a positive control triclosan dentifrice for prevention of clinical attachment loss (C

34 e only Food and Drug Administration-approved dentifrice for the treatment of plaque and gingivitis.

35 A secondary objective was to compare the dentifrices for root caries remineralization.

36 First, tetrasodium pyrophosphate in a dentifrice forms a slightly alkaline solution upon oral

37 nous fluoride stabilized with zinc phosphate dentifrice formulation demonstrated clinical reduction i

38 de and triclosan have been incorporated into dentifrice formulations and have been shown to be effect

39 individuals: 29 received the arginine-based dentifrice (group 1), 27 the strontium acetate-based den

40 ce (group 1), 27 the strontium acetate-based dentifrice (group 2), and 29 the dentifrice based on zin

41 The SnF(2) dentifrice had greater improvements in tactile scores ve

42 The SnF(2) dentifrice had greater thermal improvements than KNO(3)

43 In contrast, control dentifrice had little effect.

44 here is evidence that the use of arginine in dentifrices helps protect against caries.

45 s establish comparable benefits for the SnF2 dentifrice in preventing CAL and root caries versus the

46 % stannous fluoride/sodium hexametaphosphate dentifrice in reducing gingivitis compared to the triclo

47 ng bioactive glass, 5% CSPS, and 8% arginine dentifrice in relieving DH in patients undergoing non-su

48 D) and inflammation when used as a home care dentifrice in Stage I and II periodontitis patients.

49 rice was as effective as the 2 desensitizing dentifrices in alleviating CDS over time.

50 m sodium phosphosilicate (CSPS) and arginine dentifrices in reducing dentine hypersensitivity (DH) in

51 s study was to compare the efficacy of these dentifrices in reducing RS during daily activities in pa

52 were enrolled and randomized to one of four dentifrices in this randomized, controlled, double-blind

53 Stannous fluoride dentifrice is well established for its beneficial clinic

54 nt study is to assess the effectiveness of a dentifrice medicated with 2% atorvastatin in improving c

55 ly assigned to a toothpaste regimen: control dentifrice (n = 21) or triclosan-containing dentifrice (

56 evaluates the effect of triclosan/copolymer dentifrice on the 6-month clinical response of patients

57 m sodium phosphosilicate (CSPS) and arginine dentifrices on reducing root sensitivity (RS) following

58 nticalculus component of most tartar control dentifrices on the market today.

59 subjected to FMUD and daily use of a placebo dentifrice or to a test group (n = 15) subjected to FMUD

60 significant potential to be integrated into dentifrices or mouthrinses as an alternative non-fluorid

61 l gingivitis when participants used the test dentifrice prior to induction of experimental gingivitis

62 resent study, the use of triclosan/copolymer dentifrice promoted additional clinical benefits in the

63 The CSPS and arginine dentifrices provided comparable RS relief during daily a

64 Similarly, the CSPS dentifrice reduced RS at Week 4 and 8.

65 in group analysis revealed that the arginine dentifrice reduced RS from Week 1-8 compared with baseli

66 e the efficacy of a stannous fluoride (SnF2) dentifrice relative to a positive control triclosan dent

67 Subjects using the novel dentifrice showed significant PD reductions of 1.18 mm (

68 The novel dentifrice showed significant reductions in PD and gingi

69 SnF(2) dentifrice showed the greatest benefits for onset of rel

70 The comparison among the three dentifrices showed that, after 3 days, there was an impr

71 The Schiff analysis revealed that the CSPS dentifrice significantly reduced DH immediately and decl

72 This study documents that the three tested dentifrices significantly reduced DH after 3-day treatme

73 SnF(2), KNO(3), and oxalate dentifrices significantly reduced DH over 8 weeks.

74 tifrice was tested versus a positive control dentifrice (sodium fluoride/0.30% triclosan/copolymer) i

75 mpared with all other commercially-available dentifrices tested (p < 0.00001).

76 vailable fluoride-containing dentifrices The dentifrices tested contained: 0.454% stannous fluoride a

77 es are necessary to reverse gingivitis and a dentifrice that could provide significant clinical reduc

78 ygiene practices, including utilization of a dentifrice that could significantly improve plaque accum

79 e commercially available fluoride-containing dentifrices The dentifrices tested contained: 0.454% sta

80 hosphates have been approved as additives in dentifrices, these compounds along with the increased co

81 % stannous fluoride/sodium hexametaphosphate dentifrice to a positive control triclosan/copolymer den

82 he relative abilities of three desensitizing dentifrices to provide rapid relief of dentin hypersensi

83 n produced in this model with daily fluoride dentifrice treatments.

84 bjects were instructed to use their assigned dentifrice twice daily for 6 weeks.

85 Participants brushed with their assigned dentifrice twice daily for 8 weeks, followed by 3 weeks

86 e commercially available fluoride-containing dentifrice was as effective as the 2 desensitizing denti

87 NSPT plus 2% atorvastatin medicated dentifrice was more effective in improving clinical peri

88 % stannous fluoride/sodium hexametaphosphate dentifrice was tested against a commercially available p

89 A 0.454% SnF2/sodium hexametaphosphate dentifrice was tested versus a positive control dentifri

90 tients that were followed up to 8 weeks: all dentifrices were all highly efficacious.

91 The CSPS and arginine dentifrices were beneficial in reducing periodontitis pa

92 All dentifrices were mostly effective to reduce DH: the perc

93 controlled trial, CSPS, arginine, or control dentifrices were randomly assigned to 45 RS individuals

94 0.454% stannous fluoride and 2.6% EDTA or a dentifrice with 0.24% sodium fluoride.

95 A new dentifrice with 0.454% stannous fluoride and 2.6% EDTA d

96 and a commercially available anti-gingivitis dentifrice with 0.454% stannous fluoride.

97 effect of a new stannous fluoride-containing dentifrice with 2.6% ethylenediamine tetra acetic acid (

98 fect of a novel stannous fluoride-containing dentifrice with 2.6% ethylenediamine tetra-acetic acid (

99 A dentifrice with demonstrable clinical benefits for use b

100 nset of action, and complete relief of three dentifrices with distinct desensitizing technologies.

101 ammation over 6 months solely as a home care dentifrice without baseline SRP in Stage I and II period